Article
Mechanistic insight of predictive biomarkers for antitumor PD‑1/PD‑L1 blockade: A paradigm shift towards immunome evaluation (Review).
Oncology reports - 1 Aug 2020
You Wenjie, Shang Bin, Sun Jian, Liu Xueqing, Su Lili, Jiang Shujuan
Abstract excerpt
Checkpoint inhibitor‑based immunotherapy has exhibited unprecedented success in the treatment of advanced‑stage cancer in recent years. Several therapeutic antibodies targeting programmed death‑1 (PD‑1) or its ligand (PD‑L1) have received regulatory approvals for the treatment of multiple malignancies, including melanoma, non‑small cell lung cancer, kidney cancer and Hodgkin's lymphoma. However, a substantial...
Topics
- B7-H1 Antigen
- Biomarkers, Tumor
- Clinical Decision-Making
- DNA Mutational Analysis
- Drug Resistance, Neoplasm
- Humans
- Immune Checkpoint Inhibitors
- Mutation
- Neoplasms
- Patient Selection
- Prognosis